Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, launches Eureca-V™ Nuclease, the wild-type MAD7® CRISPR Type-V nuclease, licensed from Inscripta®, at Research Grade today with GMP to follow.
On the pathway to GMP manufacturing in support of clinical trials, multiple technology transfers may correlate to an increase in complexity and risk to both product and timeline. The hand-off of new technologies, protocols, and materials can lead to delays or project failures.
Michael Chambers, the founding CEO of Aldevron, has been elected to the board of directors for the Whitehead Institute at the Massachusetts Institute of Technology.
Developing new CRISPR/Cas9-based genome editing tools will enhance innovative therapeutic products and the pathway to clinical programs. However, current obstacles in genome editing include high error rates, toxicity from production impurities, and strict regulatory concerns.
Optimizing gene payload begins with plasmid design, and NanoplasmidsTM provide several advantages over traditional plasmids. That’s the focus of our latest webinar, done in collaboration with Phacilitate, as a panel of Aldevron experts discuss the unique opportunities associated with using nanoplasmids.
The Nanoplasmid™ vector is a high-performance <500 bp antibiotic-free bacterial backbone that, by combining the best attributes of plasmid and minicircle vectors, is designed to replace antiquated bacterial backbones that have for decades been the industry standard. The Nanoplasmid backbone is engineered to reduce plasmid associated innate immune activation which is ubiquitously associated with plasmid vectors; this translates to much lower observed toxicity and vector inactivation during primary cell transfection resulting in superior performance compared to plasmid and/or minicircle vectors with a broad range of gene and cell therapy products. This webinar will provide an overview of the Nanoplasmid technology and highlight the benefits in a variety of applications, relying on data from published studies.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Aldevron®, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, along with Inscripta®, a life science technology company dedicated to making CRISPR-based genome engineering accessible to any research lab, announced today the signing of an agreement that provides Aldevron a license to manufacture and commercialize Eureca-V™ Nuclease, the wild-type MAD7™ CRISPR Type-V nuclease.
March 22, 2022
8 am PT, 11 am ET, 16:00 CET
Messenger RNA (mRNA) and self-amplifying RNA (saRNA) unravel new possibilities for the treatment and prevention of diseases. As relatively new therapeutic modalities, both offer advantages: they can instruct the ribosome to make almost any protein, function without entering the cell nucleus, and degrade without leaving behind unwanted or harmful genetic traces. With some of the recent advances in mRNA and saRNA process technologies, we are beginning to realize the true potential of these modalities. Interestingly, saRNA also has the added advantage of lower doses compared to mRNA while getting the same effect (50-100-fold lower in some instances). However, the success of the mRNA/saRNA programs and the path to the clinic depend heavily on the timeline of manufacturing the RNA molecules.
In this GEN webinar, our distinguished speaker Dr. Venkata Indurthi will discuss some of the key upstream and downstream considerations that go into process development for RNA drug substance manufacturing. Moreover, Dr. Indurthi will also present data on the parameters that need construct-specific optimization to increase yield and reduce impurities, in addition to sharing his insights on critical aspects of analytical development to accelerate the path to the clinic.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Aldevron has acquired Nature Technology Corporation (NTC), a developer of innovative and proprietary plasmid constructs and manufacturing solutions that are used in the field of cell and gene therapy. NTC's nucleic acid-based technologies include NanoplasmidTM, a proprietary vector construct that improves the safety and performance of plasmids and biologics. Aldevron and NTC have complementary service offerings and pairing Aldevron's world-class manufacturing capabilities with NTC's innovative solutions will further support our clients and the patients they serve.
For more information about Nature Technology Corporation's full suite of offerings, visit www.natx.com
To get started now, complete the form, and a client relations representative will be in contact very soon.
Aldevron is now offering its pALD-HELP, an off-the-shelf product supporting AAV viral vector manufacturing, in its proprietary GMP-Source® (GMP-S) quality level. The plasmid is royalty-free for all applications in support of pre-clinical activities through clinical development.
The addition of this widely used plasmid expands Aldevron’s suite of ready-to-use and royalty-free constructs in support of making AAV via triple transfection, including its rep/cap plasmids 2, 5 and 6. The pALD-AAV6 plasmid is also available at the GMP-Source quality level.
“We launched this Ad helper plasmid in Research Grade as an inventory product earlier this fall and it was very well received,” said Michelle Berg, President, GMP Nucleic Acids for Aldevron. “Offering pALD-HELP in our GMP-Source quality level is another way we can support our clients in their efforts to get potential therapies to their patients sooner. Aldevron continuously looks for ways to improve our service to clients and expanding our portfolio of standardized products across quality levels ensures they have the quality products they need, when they need them.”
Aldevron has more than 23 years of experience manufacturing high-quality custom products that are used by companies around the world, along with a catalog of products that provide a consistent, reliable option to help clients meet deadlines. In addition to the AAV construct suite, Aldevron’s inventory product lines also include lentivirus plasmids, IVT enzymes, and a variety of CRISPR nucleases.
